CVS · 10-Q · 2026Q2

CVS HEALTH Corp

Filed 2026-08-05 · Consumer · View original filing on EDGAR

Ranked Events

• Legacy Litigation ChargesImportance 72 · Surprise 100
  CVS Health recorded $1.2 billion of legacy litigation charges during the six months ended June 30, 2025 related to two court decisions concerning past business practices. The charges included $929 million in the…
• Liquidity and Cash PositionImportance 69 · Surprise 64
  CVS Health held approximately $11.3 billion of cash and cash equivalents as of June 30, 2026, including approximately $2.7 billion at the parent company or unrestricted subsidiaries. Operating cash flow increased 64.2%…
• Operating Income and MarginsImportance 57 · Surprise 64
  Consolidated operating income increased 97.5% to $4.7 billion in the second quarter and 63.0% to $9.4 billion for the first six months of 2026. Consolidated operating margin expanded to 4.4% from 2.4% in the quarter…
• Medicare Advantage Payment OutlookImportance 56 · Surprise 68
  On April 6, 2026, the U.S. Centers for Medicare & Medicaid Services issued final 2027 Medicare Advantage payment rates. The final rates imply an expected average 2.48% revenue increase for the Medicare Advantage…
• Income Tax Rate ChangesImportance 55 · Surprise 82
  The effective income tax rate decreased to 24.7% in the second quarter of 2026 from 38.5% in the second quarter of 2025. For the first six months, the effective rate declined to 24.8% from 34.5%. The lower rates were…
• Pharmacy Channel DemandImportance 54 · Surprise 40
  Health Services revenue grew 11.5% in the second quarter and 11.3% for the first six months, driven primarily by pharmacy drug mix and brand inflation, despite pharmacy client price improvements. Mail and specialty…
• Revenue Performance and MixImportance 54 · Surprise 40
  Health Services revenue increased 11.5% to $51.8 billion in the second quarter and 11.3% to $100.0 billion for the first six months, driven by pharmacy drug mix and brand inflation. Health Care Benefits revenue rose…
• Capital Return ProgramImportance 50 · Surprise 24
  CVS Health had two active share repurchase authorizations totaling $20.0 billion as of June 30, 2026. The November 2022 program had $10.0 billion remaining, while the December 2021 program had $1.5 billion remaining.…
• Medical Membership TrendsImportance 39 · Surprise 50
  CVS Health had 26.0 million medical members as of June 30, 2026, including 4.2 million Medicare Advantage members, 1.2 million Medicare Supplement members, 4.3 million Medicaid members, and 18.3 million Commercial…
• Operating Expense TrendsImportance 39 · Surprise 50
  Consolidated operating expenses decreased $166 million, or 1.5%, to $11.0 billion in the second quarter and $244 million, or 1.1%, to $22.0 billion for the first six months. The quarterly reduction primarily reflected…
• PBM Legislative RestrictionsImportance 37 · Surprise 42
  Comprehensive legislation and regulations governing pharmacy benefit manager activities have been proposed or enacted in a majority of states and at the federal level. Certain states have enacted or are considering…
• Medical Benefit RatioImportance 33 · Surprise 50
  Health Care Benefits’ medical benefit ratio decreased 250 basis points to 87.4% in the second quarter of 2026 from 89.9% in the prior year. The six-month medical benefit ratio declined 260 basis points to 86.0% from…
• Interest Rate and Refinancing ExposureImportance 29 · Surprise 24
  As of June 30, 2026, CVS Health’s long-term debt was rated “BBB” by Fitch, “Baa3” by Moody’s and “BBB” by S&P. Fitch maintained a “Negative” outlook, while Moody’s outlook was “Stable” and S&P changed its outlook from…
• PBM Rebate and Pricing PressureImportance 29 · Surprise 24
  CVS Caremark continues to share a larger portion of pharmaceutical-manufacturer rebates, fees and discounts with clients and typically provides minimum pricing guarantees. Management said these guarantees cannot always…
• Medical Utilization PressureImportance 29 · Surprise 24
  Medical utilization remained elevated in the second quarter of 2026, creating potential pressure on the Health Care Benefits segment and CVS Healths health care delivery assets. Management stated that utilization…
• Retail Pharmacy DemandImportance 25 · Surprise 32
  Pharmacy same-store sales increased 2.9% in the second quarter and 3.0% for the first six months, supported by pharmacy drug mix, brand inflation and prescription-volume growth. Pharmacy same-store prescription volume…
• Tariff and Inflation ExposureImportance 23 · Surprise 24
  CVS Health identified inflation, new or changed tariffs, and U.S. trade relations with foreign countries as factors that could increase costs and disrupt supply chains. These effects could adversely affect consumer…
• 340B Program UncertaintyImportance 23 · Surprise 24
  The federal 340B drug pricing program remains a dynamic regulatory environment. CVS Health stated that developments in the program may continue to affect its Health Services segment, which provides administrative,…
• DividendsImportance 19 · Surprise 6
  CVS Health declared a quarterly cash dividend of $0.665 per share in the three months ended June 30, 2026, unchanged from the same period in 2025. Cash dividends declared totaled $1.33 per share for the six months…
• Liquidity and Debt PositionImportance 19 · Surprise 6
  CVS Health had no commercial paper outstanding and no borrowings under its three unsecured back-up revolving credit facilities as of June 30, 2026. Each facility provides $2.5 billion of capacity and expires in May…

Revenue by Product (in millions)